Program
varegacestat
Also written as “AL102” and “BMS-986115”.
Its studies are mostly in Desmoid Tumors, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Immunome | 51 open or running | phase 3since Apr 23, 2021 | Apr 23, 2021 | none ahead |
| Bristol-Myers Squibb | 10 open or running | phase 1since Nov 11, 2013 | Nov 11, 2013 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 11, 2013First study: phase 1 study in Various Advanced CancerNew to Bristol-Myers SquibbBristol-Myers Squibb · NCT01986218 · 36 enrolled · United States, Australia, Canada
- Apr 23, 2021Immunome's first study: phase 3 study in Desmoid TumorsNew to ImmunomeImmunome · NCT04871282 · 198 enrolled · United States, Australia, Belgium and more
- Nov 4, 2024Phase 1 study in Healthy VolunteerImmunome · NCT06677996 · 22 enrolled · United States
- Jan 24, 2025Phase 1 study in Healthy VolunteerImmunome · NCT06841315 · 35 enrolled · United States
- Feb 5, 20252 phase 1 studies in Healthy VolunteerImmunome · NCT06845852, NCT06855264
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06855264Healthy Volunteer · United States | 1 | Completed | Immunome | Apr 8, 2025 | 32 |
| NCT06845852Healthy Volunteer · United States | 1 | Completed | Immunome | Mar 11, 2025 | 6 |
| NCT06841315Healthy Volunteer · United States | 1 | Completed | Immunome | Nov 5, 2025 | 35 |
| NCT06677996Healthy Volunteer · United States | 1 | Completed | Immunome | Dec 30, 2024 | 22 |
| NCT04871282Desmoid Tumors · United States, Australia, Belgium and more | 3 | Active, not recruiting | Immunome | Dec 3, 2025 | 198 |
| NCT01986218Various Advanced Cancer · United States, Australia, Canada | 1 | Terminated | Bristol-Myers Squibb | Mar 2016 | 36 |
How it is read
Names in the registry
- “varegacestat”, 4 entries
- “AL102”, 1 entry
- “BMS-986115”, 1 entry
Conditions, from the studies’ own filings
- Desmoid Tumors, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.